What Is PT-141?
PT-141 (Bremelanotide) is a synthetic melanocortin peptide that acts on the central nervous system to increase sexual desire. Unlike PDE5 inhibitors (Viagra, Cialis) that work on blood flow mechanics, PT-141 targets the brain's arousal pathways — making it effective for desire-based sexual dysfunction rather than just performance mechanics.
It's FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of very few peptides with an FDA-approved indication specifically for women.
Mechanism of Action
- MC3R/MC4R activation: PT-141 activates melanocortin receptors 3 and 4 in the hypothalamus — the brain region governing sexual arousal and desire
- Dopamine pathway modulation: Increases dopaminergic signaling associated with motivation and reward, enhancing desire at the neurological level
- Central, not peripheral: Works in the brain, not on vascular smooth muscle. This is why it addresses desire rather than blood flow
- Gender-neutral mechanism: The melanocortin pathway governs arousal in both men and women, though the FDA approval is specifically for women with HSDD
PT-141 vs PDE5 Inhibitors
| Factor | PT-141 (Bremelanotide) | Viagra/Cialis (PDE5i) |
|---|---|---|
| Target | Brain (melanocortin receptors) | Blood vessels (PDE5 enzyme) |
| Addresses | Desire / arousal / libido | Erectile mechanics / blood flow |
| Works for women? | Yes — FDA-approved for HSDD in women | Limited evidence in women |
| Administration | Subcutaneous injection (45 min before) | Oral (30-60 min before) |
| Duration | Up to 24 hours | 4-36 hours depending on compound |
| Common side effects | Nausea, flushing, headache | Headache, flushing, nasal congestion |
Clinical Evidence
Women (HSDD)
The RECONNECT Phase 3 trials demonstrated that PT-141 significantly increased the number of satisfying sexual events and sexual desire scores in premenopausal women with HSDD compared to placebo. This led to FDA approval of Vyleesi in 2019.
Men (Erectile Dysfunction)
Clinical trials in men showed PT-141 induced erections in patients with erectile dysfunction, including some who did not respond to PDE5 inhibitors. While not FDA-approved for men, it's available through compounding pharmacies and research suppliers for this application.
Dosing & Administration
| Use | Dose | Timing | Frequency Limit |
|---|---|---|---|
| FDA-approved (women) | 1.75 mg SC | 45 minutes before activity | Max 1 dose per 24h, max 8 doses/month |
| Research (men) | 1-2 mg SC | 30-60 min before | As needed, not daily |
Side Effects
- Nausea: The most common side effect (~40% in trials). Usually mild and transient. Taking an anti-nausea medication beforehand can help.
- Flushing: Facial and body flushing (~20%). Related to melanocortin receptor activation.
- Headache: Moderate frequency (~10-15%)
- Injection site reactions: Mild redness, standard for SC injections
- Skin darkening: With repeated use, some darkening of skin/gums has been observed (melanocortin pathway). Less pronounced than Melanotan II.
Where to Source PT-141
Frequently Asked Questions
Related Articles
Not Sure Which Peptide Is Right for You?
Take our free 60-second quiz and get personalized recommendations based on your goals.
Take the Quiz →